News
IONS
73.72
+0.24%
0.18
Fonds de solidarité FTQ joins $20 million CELYSTRA Pharma financing round
PUBT · 8h ago
Ionis Pharmaceuticals director Peter N. Reikes files initial beneficial ownership statement
PUBT · 1d ago
Ionis Pharmaceuticals director Ludwig Hantson files initial beneficial ownership statement
PUBT · 1d ago
Ionis Pharmaceuticals Adds Veteran Leader to Board
TipRanks · 1d ago
Ionis adds former Alexion CEO Ludwig Hantson to board
PUBT · 1d ago
Ionis Pharmaceuticals appoints Hantson to Board of Directors
TipRanks · 1d ago
IONIS ANNOUNCES APPOINTMENT OF LUDWIG HANTSON, PH.D. TO BOARD OF DIRECTORS
Reuters · 1d ago
*Ionis Announces Appointment of Ludwig Hantson to Bd of Directors
Dow Jones · 1d ago
Weekly Report: what happened at IONS last week (0601-0605)?
Weekly Report · 1d ago
How Ionis’s Advancing Antisense Pipeline and Olezarsen Milestones Will Impact Ionis Pharmaceuticals (IONS) Investors
Simply Wall St · 2d ago
Ionis Pharmaceuticals: Buy Rating Reiterated on Strong Pipeline, Near-Term Catalysts, and Unchanged $110 Price Target
TipRanks · 4d ago
Ionis Pharmaceuticals (IONS) Receives a Buy from Guggenheim
TipRanks · 4d ago
A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong Long Term Shareholder Returns
Simply Wall St · 4d ago
Ionis posts presentation for 2026 annual shareholders meeting
PUBT · 5d ago
Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen
Dow Jones · 5d ago
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Barchart · 5d ago
Ionis director Spencer R. Berthelsen disposes of 8,000 common shares for $605,360
PUBT · 6d ago
Ionis Pharmaceuticals Price Target Maintained With a $125.00/Share by HC Wainwright & Co.
Dow Jones · 06/01 11:45
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $125 Price Target
Benzinga · 06/01 11:35
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX)
TipRanks · 06/01 10:30
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.